Anthony Y. Sun, M.D. served as the CEO of Zentalis Pharmaceuticals from 2014 until May 2022. He has an impressive background that combines medicine and business. With an M.D. from the renowned Mayo Clinic Medical School, Dr. Sun has significant...

Anthony Y. Sun, M.D. served as the CEO of Zentalis Pharmaceuticals from 2014 until May 2022. He has an impressive background that combines medicine and business. With an M.D. from the renowned Mayo Clinic Medical School, Dr. Sun has significant expertise in the life sciences. Before leading Zentalis, he held various positions, including being a partner at Aisling Capital, where he invested in life science companies. He was also involved with the Perseus-Soros BioPharmaceutical Fund, providing him a good mix of clinical and financial insight. In 2021, his total compensation was around $5.9 million, reflecting his key role in guiding the company through vital developments in its drug pipeline. Dr. Sun is known for making strategic moves, including a notable industry collaboration with Tempus for improving cancer therapies. His work with Zentalis has escalated the company’s profile in oncology, aiming to create innovative treatments across various cancer types. After his tenure, Dr. Sun is continuing to impact the industry and serve on multiple boards, proving his importance in the life sciences sector.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Zentalis Pharmaceuticals, Inc. CEOs

Z

Anthony Y. Sun, M.D.

Ex-CEO of Zentalis Pharmaceuticals, Inc.

Education

M.D. from Harvard Medical School

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1972 - 53 years ago

CEO of Zentalis Pharmaceuticals, Inc. for

2 years 4 months (Jan 2020 - May 2022)

Previous Experience

Various leadership roles in biopharmaceutical companies

Rivals

Competitors/colleagues of Anthony Y. Sun, M.D.

Holdings

See how much did Anthony Y. Sun, M.D. make over time.

At his peak, Dr. Sun held substantial positions in Zentalis' stocks, reflecting his deep commitment to the company. His insider trading showed fluctuations in his holdings, peaking at around $210.94 million in December 2020. Following that, over the next couple...

At his peak, Dr. Sun held substantial positions in Zentalis' stocks, reflecting his deep commitment to the company. His insider trading showed fluctuations in his holdings, peaking at around $210.94 million in December 2020. Following that, over the next couple of years, the value dropped significantly, with values reaching as low as $30.21 million by late 2023. This decrease illustrates the volatile nature of the biotech field, but it also underscores Dr. Sun's hands-on investment in Zentalis, playing a critical role in its growth and challenges. After his departure, he retained some vested interests, indicating a continued belief in the company's potential.

Mar 17, 2025

Z

shares

ZNTL @ $1.89

Total Stock Sold

$32.85M

ZNTL

$32.85M

607,910 ZNTL shares

What if they kept their stock?

If Anthony Y. Sun, M.D. didn't sell their stock, today they would have:
Extra ZNTL607,910 shares worth $28.50M.
This is -13.24% and $4.35M less than what they got when they sold the stock.

Charitable Transactions

ZNTL

493,650 shares

ZNTL

Recent Charitable Transactions

ZNTL

15,000 shares

ZNTL

Jan 3, 2022

Charity

ZNTL

125,000 shares

ZNTL

Dec 1, 2021

Charity

ZNTL

125,000 shares

ZNTL

Dec 1, 2021

Charity

ZNTL

228,650 shares

ZNTL

May 3, 2021

Charity

ZNTL

213,600 shares

ZNTL

Jan 4, 2021

Charity

Insider Trading

See recent insider trades of Anthony Y. Sun, M.D..

ZNTL

$1.06M

ZNTL at $50.65/share

Apr 4, 2022

Sale

ZNTL

$1.05M

ZNTL at $50.20/share

Mar 1, 2022

Sale

ZNTL

$238.81K

ZNTL at $50.46/share

Feb 10, 2022

Sale

ZNTL

50,431 shares

ZNTL

Feb 10, 2022

Received

ZNTL

$1.22M

ZNTL at $58.08/share

Feb 1, 2022

Sale

ZNTL

$1.68M

ZNTL at $80.15/share

Jan 3, 2022

Sale

ZNTL

15,000 shares

ZNTL

Jan 3, 2022

Charity

ZNTL

$1.61M

ZNTL at $76.76/share

Dec 1, 2021

Sale

ZNTL

125,000 shares

ZNTL

Dec 1, 2021

Charity

ZNTL

125,000 shares

ZNTL

Dec 1, 2021

Charity

Compensation History

See how much did Anthony Y. Sun, M.D. make over time.

In 2022, Dr. Sun's total compensation was around $9 million, including a salary of $693,800 and a large severance package due to his resignation. The bonus he received represented a target payout for the year even though he left before its conclusion, valuing his leadership. In 2021, he earned $5.9 million primarily through stock awards that were tied to the company's performance. These compensations include a mix of cash and equity, reflecting the company's strategy to align executive pay with the long-term success of its projects. Over his tenure, Dr. Sun has shown that he can lead Zentalis through innovative product development while maintaining a strong financial stake in the company.

Year

2022

Total Compensation

$3.70M

Salary

$693.80K

Board Justification

The compensation philosophy aims to align executive compensation with company performance and market benchmarks, ensuring competitive pay to attract and retain top talent.

Bonus

$143.70K

Board Justification

This amount represents the prorated target bonus for 2022, as Dr. Sun resigned before the end of the fiscal year.

Other

$1.19M

Board Justification

This includes a lump sum cash severance payment in the amount of $1,184,455 in accordance with Dr. Sun's Release Agreement, plus other benefits.

Restricted Stock

$1.67M(83.24K RSU)

Board Justification

The value of Dr. Sun’s outstanding RSUs and restricted stock was calculated based on the closing price of our Common Stock on December 30, 2022, multiplied by the number of RSUs vested.

Performance Metrics

The performance metrics for determining the compensation included achievement of corporate performance goals.

Other Zentalis Pharmaceuticals, Inc. CEOs

Here are other CEOs of Zentalis Pharmaceuticals, Inc.

Kimberly Blackwell, M.D.

Ex-CEO of Zentalis Pharmaceuticals, Inc.

May 2022 - November 2024